Early complete response of primary bone marrow B-cell lymphoma treated with Rituximab-based CHOP therapy, assessed by flow cytometry and IGH rearrangement

Primary bone marrow B-cell lymphoma (PBML) is a special subtype of DLBCL which can be repeatedly sampled and evaluated by FCM and IGH rearrangement. Evaluation of early response by FCM and IGH assessments in the midpoint of treatment could be valuable for predicting treatment outcome.